Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cyclobenzaprine
Drug ID BADD_D00545
Description Cyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961[A185039] and has been available for human use since 1977.[A184982] It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from [Amitriptyline] by only a single double bond.[A185039,A184982] Since its approval, it has remained relatively popular as an adjunctive, short-term treatment for acute skeletal muscle spasms secondary to musculoskeletal injury.
Indications and Usage For use as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions.
Marketing Status Prescription; Discontinued
ATC Code M03BX08
DrugBank ID DB00924
KEGG ID D07758
MeSH ID C004704
PubChem ID 2895
TTD Drug ID D01KHH
NDC Product Code 68071-3150; 63187-812; 0615-8084; 61919-305; 69097-845; 69097-846; 51927-0118; 70518-0635; 58118-0846; 53002-3080; 53002-0521; 67296-1728; 70518-3159; 68071-3154; 60687-558; 50090-3253; 70934-005; 70518-0082
Synonyms cyclobenzaprine | Flexeril | Lisseril | cyclobenzaprine hydrochloride
Chemical Information
Molecular Formula C20H21N
CAS Registry Number 303-53-7
SMILES CN(C)CCC=C1C2=CC=CC=C2C=CC3=CC=CC=C31
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Confusional state19.13.01.001; 17.02.03.0050.000262%
Constipation07.02.02.001--
Coordination abnormal17.02.02.004--Not Available
Death08.04.01.0010.000222%
Delirium19.13.02.0010.000295%
Delusion19.10.01.0010.000098%
Depressed level of consciousness17.02.04.0020.000086%
Depressed mood19.15.02.001--Not Available
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.001--
Diplopia06.02.06.002; 17.17.01.005--Not Available
Discomfort08.01.08.003--Not Available
Disorientation19.13.01.002; 17.02.05.0150.000066%Not Available
Disturbance in attention19.21.02.002; 17.03.03.001--
Dizziness17.02.05.003; 02.01.02.004; 24.06.02.0070.000328%
Drug abuse19.07.02.0100.000334%Not Available
Drug hypersensitivity10.01.01.0010.001902%Not Available
Drug withdrawal syndrome19.07.02.011; 08.06.02.004--Not Available
Dry mouth07.06.01.002--
Dry skin23.03.03.0010.000098%
Dry throat22.02.05.004; 07.06.01.005--Not Available
Dysarthria19.19.03.001; 17.02.08.001--
Dysgeusia17.02.07.003; 07.14.03.001--
Dyspepsia07.01.02.001--
Dyspnoea22.02.01.004; 02.01.03.002--
Electrocardiogram abnormal13.14.05.0010.000164%Not Available
Electrocardiogram QRS complex prolonged13.14.05.0030.000197%Not Available
Electrocardiogram QT prolonged13.14.05.0040.000034%
Encephalopathy17.13.02.0010.000066%
Eosinophilia01.02.04.001--
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 7 Pages